Watson Pharmaceuticals Inc ships generic MARINOL capsules

Jul 01, 2008 (M2 EQUITYBITES via COMTEX) -- WPI | Quote | Chart | News | PowerRating -- Watson Pharmaceuticals Inc (NYSE: WPI), a speciality pharmaceutical company, said on 30 June that the company has entered into a supply agreement with Solvay Pharmaceuticals Inc for the former's generic dronabinol in the 2.5, 5 and 10 mg once daily dosage strengths.

Dronabinol is the generic version of Solvay Pharmaceuticals' MARINOL (dronabinol) CIII Capsules, which, for the 12-months ending December 2007, had sales of EUR105m. It is indicated to treat nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Also it is indicated to treat anorexia associated with weight loss in patients with acquired immunodeficiency syndrome (AIDS). The agreement enables Solvay Pharmaceuticals to supply the dronabinol capsules to the company's subsidiary, Watson Pharma, which will market, sell and distribute the product in the United States. In return, Solvay Pharmaceuticals will receive a share of the profits from Watson's sales of the generic product in the US market.

Comments on this story may be sent to admin@m2.com

Morning Coffee with TradingMarkets -- Free Newsletter

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index